UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of July 2019
Commission File Number: 001-37847
MOTIF BIO PLC
(Translation of registrant's name into English)
125 Park Avenue
25th Floor
New York, New York 10017
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
MOTIF BIO PLC
FORM 6-K
MOTIF BIO CONFIRMS MEETING DATE WITH U.S. FDA REGARDING ICLAPRIM
On July 26, 2019, Motif Bio plc (the “Company”) issued a press release to announce that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type B meeting related to a proposed clinical study for the Company’s lead product candidate, iclaprim. The in person meeting has been scheduled for September 19, 2019. The Company also plans to discuss the proposed patient population and study design with the FDA at the upcoming meeting. The press release is attached hereto as Exhibit 99.1.
The information contained in this report on Form 6-K, including the press release attached as Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-222614 and 333-222042), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibits
| Exhibit 99.1 | Press release issued by Motif Bio plc, dated July 26, 2019, entitled “Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | MOTIF BIO PLC |
| | | |
| | | |
| Date: July 26, 2019 | By: | /s/ Graham Lumsden |
| | Name: | Graham Lumsden |
| | Title: | Chief Executive Officer |
| | | |
